AbbVie Inc. (NYSE:ABBV) Is Alpha Omega Wealth Management LLC's 7th Largest Position
AbbVie Inc. (NYSE:ABBV) Is Alpha Omega Wealth Management LLC's 7th Largest Position
Alpha Omega Wealth Management LLC decreased its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,270 shares of the company's stock after selling 1,216 shares during the quarter. AbbVie makes up 1.8% of Alpha Omega Wealth Management LLC's portfolio, making the stock its 7th biggest holding. Alpha Omega Wealth Management LLC's holdings in AbbVie were worth $9,997,000 as of its most recent filing with the Securities & Exchange Commission.
據阿爾法-歐米茄財富管理有限責任公司在提交給美國證券交易委員會的最新Form 13F文件中稱，該公司在第二季度減持了艾伯維公司的股份1.8%。該機構投資者在本季度出售了1216股後，持有該公司65,270股股票。AbbVie佔Alpha Omega Wealth Management LLC投資組合的1.8%，使該股成為其第7大持股。Alpha Omega Wealth Management LLC在最近提交給美國證券交易委員會的文件中，持有的艾伯維股份價值999.7萬美元。
Other hedge funds and other institutional investors have also bought and sold shares of the company. Thrive Wealth Management LLC increased its position in AbbVie by 10.3% in the second quarter. Thrive Wealth Management LLC now owns 3,391 shares of the company's stock worth $519,000 after buying an additional 318 shares in the last quarter. Sound Income Strategies LLC increased its position in AbbVie by 2.5% in the second quarter. Sound Income Strategies LLC now owns 84,866 shares of the company's stock worth $12,998,000 after buying an additional 2,058 shares in the last quarter. HB Wealth Management LLC increased its position in AbbVie by 40.7% in the second quarter. HB Wealth Management LLC now owns 63,498 shares of the company's stock worth $9,725,000 after buying an additional 18,353 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of AbbVie by 2.9% during the second quarter. Parkside Financial Bank & Trust now owns 8,697 shares of the company's stock worth $1,332,000 after purchasing an additional 242 shares in the last quarter. Finally, Minot Wealth Management LLC grew its position in shares of AbbVie by 1.2% during the first quarter. Minot Wealth Management LLC now owns 66,161 shares of the company's stock worth $10,725,000 after purchasing an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 68.25% of the company's stock.
其他對衝基金和其他機構投資者也買賣了該公司的股票。Thrive Wealth Management LLC在第二季度將其在AbbVie的頭寸增加了10.3%。Thrive Wealth Management LLC現在擁有3391股該公司股票，價值51.9萬美元，上個季度又購買了318股。穩健收入策略有限責任公司在第二季度將其在AbbVie的頭寸增加了2.5%。Sound Income Strategy LLC現在擁有84,866股該公司股票，價值12,998,000美元，上個季度又購買了2,058股。HB Wealth Management LLC在第二季度將其在AbbVie的頭寸增加了40.7%。HB Wealth Management LLC現在持有63,498股該公司股票，價值9,725,000美元，上個季度又購買了18,353股。Parkside Financial Bank&Trust在第二季度將其在AbbVie股票的頭寸增加了2.9%。Parkside Financial Bank&Trust現在持有該公司8,697股股票，價值1,332,000美元，上個季度又購買了242股。最後，Minot Wealth Management LLC在第一季度將其在AbbVie股票中的頭寸增加了1.2%。Minot Wealth Management LLC現在擁有66,161股該公司股票，價值10,725,000美元，上個季度又購買了800股。對衝基金和其他機構投資者持有該公司68.25%的股票。
AbbVie Price Performance
AbbVie性價比
NYSE:ABBV opened at $134.21 on Friday. The firm has a market capitalization of $237.30 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 4.01 and a beta of 0.72. AbbVie Inc. has a 1 year low of $106.86 and a 1 year high of $175.91. The business has a 50 day simple moving average of $141.00 and a 200-day simple moving average of $149.13. The company has a debt-to-equity ratio of 4.15, a current ratio of 0.84 and a quick ratio of 0.75.
紐約證券交易所：ABBV週五開盤報134.21美元。該公司市值為2,373億美元，市盈率為19.01倍，市盈率為4.01倍，貝塔係數為0.72。艾伯維公司的股價一年來最低為106.86美元，一年最高為175.91美元。該業務的50日簡單移動均線切入位在141.00美元，200日簡單移動均線切入位在149.13美元。該公司的債務權益比為4.15，流動比率為0.84，速動比率為0.75。
AbbVie Dividend Announcement
AbbVie股息公告
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Stockholders of record on Friday, October 14th will be paid a $1.41 dividend. This represents a $5.64 annualized dividend and a dividend yield of 4.20%. The ex-dividend date is Thursday, October 13th. AbbVie's payout ratio is 79.89%.
該業務最近還披露了季度股息，將於11月15日(星期二)支付。10月14日(星期五)登記在冊的股東將獲得1.41美元的股息。這意味着5.64美元的年化股息和4.20%的股息收益率。除息日期為10月13日星期四。艾伯維的派息率為79.89%。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several analysts recently issued reports on the company. UBS Group cut their target price on AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a research report on Monday, August 1st. Morgan Stanley cut their target price on AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a research report on Monday, August 1st. Atlantic Securities cut their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a research report on Monday, August 1st. Barclays cut their target price on AbbVie to $160.00 in a research report on Tuesday, August 9th. Finally, Argus cut their target price on AbbVie from $165.00 to $155.00 and set a "buy" rating for the company in a research report on Wednesday, August 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $159.35.
幾位分析師最近發佈了有關該公司的報告。瑞銀集團8月1日週一在一份研究報告中將AbbVie的目標價從154.00美元下調至146.00美元，並將該公司的評級定為“中性”。8月1日，摩根士丹利在一份研究報告中將艾伯維的目標價從191.00美元下調至188.00美元，並對該公司設定了“增持”評級。大西洋證券8月1日週一在一份研究報告中將AbbVie的目標價從178.00美元下調至162.00美元，並將該公司的評級定為“中性”。巴克萊在8月9日週二的一份研究報告中將AbbVie的目標價下調至160.00美元。最終，阿格斯在8月24日(週三)的一份研究報告中將AbbVie的目標價從165.00美元下調至155.00美元，並對該公司設定了“買入”評級。一名投資分析師對該股的評級為賣出，6名分析師給予持有評級，9名分析師給予買入評級，一名分析師給予該股強烈買入評級。根據MarketBeat的數據，該公司目前的平均評級為“適度買入”，共識目標價為159.35美元。
AbbVie Company Profile
艾伯維公司簡介
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。